GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Overview
Mermaid diagram (expand to render)
The LIGHT-COG Study (NCT07083154) is a Phase 3 clinical trial investigating the efficacy, safety, and tolerability of a GLP-1/GCG (Glucagon) Dual Receptor Agonist in patients with Type 2 Diabetes and early dementia, particularly Alzheimer's disease["@diabetes2021"].
This trial represents a novel therapeutic approach targeting the metabolic dysfunction hypothesis of neurodegeneration, leveraging the neuroprotective effects of GLP-1 receptor agonism. It is one of the first large-scale Phase 3 trials to directly test whether metabolic modulation can slow cognitive decline in AD patients with diabetes.
| Field | Value |
|-------|-------|
| NCT Number | [NCT07083154](https://clinicaltrials.gov/study/NCT07083154) |
| Status | Recruiting |
| Phase | Phase 3 |
| Enrollment | 420 participants (estimated) |
| Study Type | Interventional |
| Allocation | Randomized, parallel-group |
| Intervention Model | Double-blind, placebo-controlled |
| Start Date | September 27, 2025 |
| Completion Date | August 1, 2029 |
| Primary Outcome | Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change[@iadrsscale] |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Study Design
Arms
| Arm | Intervention | Dose | Duration |
|-----|--------------|------|----------|
| Active | GLP-1/GCG Dual Agonist | TBD | 52 weeks |
| Placebo | Matching placebo | N/A | 52 weeks |
Primary Endpoint
- Change in iADRS (Integrated Alzheimer's Disease Rating Scale) score from baseline to Week 52
- The iADRS combines cognitive testing (ADAS-Cog) with functional assessment (ADCS-ADL)
Secondary Endpoints
| Endpoint | Measure | Timepoint |
|----------|---------|-----------|
| Cognition | MMSE | Baseline, Week 26, Week 52 |
| Cognition | ADAS-Cog13 | Baseline, Week 52 |
| Function | ADCS-ADL | Baseline, Week 52 |
| Global | CDR-SB | Baseline, Week 52 |
| Brain imaging | Hippocampal volume (MRI) | Baseline, Week 52 |
| Biomarkers | CSF Aβ40, Aβ42, total tau, p-tau181 | Baseline, Week 52 |
| Biomarkers | Plasma Aβ, p-tau, NfL | Baseline, Week 26, Week 52 |
Eligibility Criteria
Inclusion Criteria
Age 55-85 years
Diagnosis of mild cognitive impairment (MCI) due to AD or mild dementia due to AD (NIA-AA criteria)
Confirmed Type 2 Diabetes (HbA1c 6.5-8.5%)
MMSE score 20-28
Stable diabetes medication for ≥8 weeks prior to screening
Have a reliable caregiver/informantExclusion Criteria
Diagnosis of non-AD dementia
History of Type 1 diabetes or diabetic ketoacidosis
Severe cardiovascular disease (NYHA Class III-IV, recent MI)
History of pancreatitis
Active cancer or cancer within 5 years
MRI evidence of significant vascular diseaseScientific Rationale
Type 2 Diabetes and Alzheimer's Disease Link
Epidemiological studies have established a strong link between Type 2 Diabetes and increased risk of Alzheimer's disease. The metabolic dysfunction in diabetes contributes to[@type3diabetes]:
Impaired glucose metabolism in the brain
- Brain insulin resistance reduces glucose utilization
- Neuronal energy crisis contributes to dysfunction
- Impaired insulin signaling affects synaptic plasticity
Increased neuroinflammation
- Chronic low-grade inflammation in diabetes
- Activated microglia produce pro-inflammatory cytokines
- Neuroinflammation accelerates tau pathology
Oxidative stress
- Mitochondrial dysfunction from chronic hyperglycemia
- Advanced glycation end-products (AGEs) accumulate
- Antioxidant systems become overwhelmed
Blood-brain barrier dysfunction
- Diabetes impairs endothelial function
- Reduced clearance of Aβ from brain
- Increased leakiness allows peripheral toxins into CNS
The "Type 3 Diabetes" Hypothesis
Emerging evidence supports the concept of Alzheimer's disease as a form of diabetes[@type3diabetes]:
- Brain insulin resistance: AD brains show reduced insulin receptor expression and signaling
- Impaired glucose uptake: FDG-PET shows hypometabolism in AD-affected regions
- Aβ effects on insulin signaling: Aβ oligomers interfere with insulin receptor function
- Tau effects on glucose metabolism: Tau pathology disrupts insulin signaling
GLP-1 Receptor Agonists as Neuroprotective Agents
GLP-1 receptor agonists, originally developed for diabetes treatment, have shown neuroprotective properties in preclinical models[@glp1neuroprotection]:
| Mechanism | Effect |
|-----------|--------|
| Insulin sensitization | Enhances brain insulin sensitivity |
| Anti-inflammatory | Reduces microglial activation |
| Anti-apoptotic | Prevents neuronal death |
| Synaptic protection | Preserves synaptic function |
| Aβ reduction | Decreases amyloid plaque formation |
| Tau modulation | Reduces tau phosphorylation |
| Autophagy enhancement | Improves protein clearance |
| Mitochondrial function | Preserves neuronal energy metabolism |
Why Dual GLP-1/GCG Agonism?
The dual GLP-1/GCG agonist may provide enhanced neuroprotection:
GLP-1 Receptor Effects
- Enhances insulin sensitivity in the brain
- Reduces neuroinflammation
- Promotes synaptic plasticity and neurogenesis
- Decreases amyloid-beta toxicity
GCG Receptor Effects
- Regulates glucose metabolism
- Modulates hepatic glucose output
- May improve cerebral energy metabolism
- Enhances lipolysis and energy expenditure
The dual mechanism addresses both peripheral and central metabolic dysfunction, which are increasingly recognized as key contributors to Alzheimer's disease pathogenesis[@metabolicad].
Clinical Sites
Participating Institutions (China)
| Institution | City | Province |
|-------------|------|----------|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University | Nanjing | Jiangsu |
| Nanjing First Hospital, Nanjing Medical University | Nanjing | Jiangsu |
| Shanghai General Hospital, Shanghai Jiao Tong University | Shanghai | Shanghai |
| Xiangya Hospital of Central South University | Changsha | Hunan |
| Huadong Hospital | Nanjing | Jiangsu |
| Jiangsu Province Hospital of Traditional Chinese Medicine | Nanjing | Jiangsu |
| Changzhou No.2 People's Hospital | Changzhou | Jiangsu |
| The Second Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |
Biomarker Program
Target Engagement
| Biomarker | Sample | Expected Change |
|-----------|--------|-----------------|
| HbA1c | Blood | Reduced |
| Fasting glucose | Blood | Reduced |
| GLP-1 levels | Plasma | Increased |
Disease Progression Markers
| Biomarker | Sample | Purpose |
|-----------|--------|---------|
| Aβ40/Aβ42 | CSF | Amyloid burden |
| Total tau | CSF | Neurodegeneration |
| p-tau181 | CSF | Tau pathology |
| NfL | Plasma | Axonal injury |
| Neurogranin | CSF | Synaptic dysfunction |
Imaging
- MRI: Hippocampal atrophy rate
- FDG-PET: Cerebral glucose metabolism
- Amyloid PET: (subset) Amyloid plaque burden
Competitive Landscape
GLP-1 Agonists in Alzheimer's Disease
| Drug | Company | Phase | Status | Mechanism |
|------|---------|-------|--------|-----------|
| LIGHT-COG | Nanjing Drum Tower | Phase 3 | Recruiting | GLP-1/GCG dual |
| Semaglutide | Novo Nordisk | Phase 3 | Completed | GLP-1 |
| Liraglutide | Novo Nordisk | Phase 2 | Completed | GLP-1 |
| Exenatide | AstraZeneca | Phase 2 | Completed | GLP-1 |
| Dapagliflozin | BMS | Phase 2 | Recruiting | SGLT2 |
| Approach | Target | Development Stage |
|----------|--------|------------------|
| GLP-1/GIP dual | GLP-1/GIP receptors | Phase 2-3 |
| GLP-1/GCG dual | GLP-1/GCC receptors | Phase 3 |
| SGLT2 inhibitors | Glucose reabsorption | Phase 2 |
| Insulin sensitizers | PPARγ | Phase 2 |
| Metabolic modulators | mTOR, AMPK | Preclinical |
Why This Trial Matters
1. Addressing the Comorbidity
- ~30% of AD patients have Type 2 Diabetes
- Diabetes accelerates cognitive decline
- No approved therapies addressing this comorbidity
2. Disease-Modifying Potential
- Targets underlying metabolic dysfunction rather than just symptoms
- Addresses both peripheral and central pathology
- May slow progression rather than merely symptomatic benefit
3. Large Phase 3 Trial
- 420 participants provides robust efficacy data
- 52-week duration adequate for detecting clinical benefit
- Comprehensive biomarker program to understand mechanism
4. Unmet Medical Need
- No approved therapies for Alzheimer's that target metabolic pathways
- Current AD treatments (cholinesterase inhibitors, memantine) provide limited benefit
- Metabolic approaches offer a novel mechanism of action
5. Potential for Precision Medicine
- May identify responders based on metabolic status
- Biomarker program will inform personalized treatment approaches
- Could lead to combination therapies for diabetes-AD patients
Safety Considerations
Expected Adverse Events
| Event | Frequency | Management |
|-------|-----------|------------|
| Nausea | Common (20-30%) | Gradual titration, anti-emetics |
| Vomiting | Less common (5-10%) | Dose adjustment |
| Diarrhea | Common (10-15%) | Supportive care |
| Hypoglycemia | Rare (2-3%) | Monitor, adjust diabetes meds |
| Pancreatitis | Rare (<1%) | Immediate discontinuation |
Monitoring Plan
- Regular blood glucose monitoring
- Adverse event assessment at each visit
- Pancreatic enzyme monitoring (amylase, lipase)
- Cardiovascular monitoring (ECG, vital signs)
Regulatory Considerations
China NMPA Context
- This trial is conducted under China NMPA regulations
- Results may support approval in China
- International multi-regional trials may follow
Potential for Global Development
- Success could lead to global Phase 3 program
- GLP-1 agonists have established safety profiles
- May pursue FDA/EMA approval for AD indication
Current Status (March 2026)
The LIGHT-COG trial is actively recruiting as of March 2026. Enrollment is expected to complete by mid-2027, with topline results in 2029.
Milestones:
- September 2025: First patient enrolled
- December 2025: 50 patients enrolled
- Target: 420 patients by mid-2027
Clinical Significance
This trial is significant because:
First large-scale Phase 3 testing metabolic therapy in AD with diabetes
Novel mechanism targeting brain insulin resistance
Addresses comorbidity affecting millions of AD patients
May establish new treatment paradigm for AD
Biomarker-rich design will elucidate mechanismIf Positive
- Would support "Type 3 diabetes" hypothesis
- Could lead to GLP-1 agonist approval for AD
- Would validate metabolic approach more broadly
- May expand to non-diabetic AD patients
If Negative
- Would not necessarily refute metabolic hypothesis
- Could indicate wrong target or inadequate dosing
- May inform combination therapy approaches
- Would guide future trial designs
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
- [Type 3 Diabetes Hypothesis](/mechanisms/type-3-diabetes-ad) — Mechanism
- [GLP-1 and Neuroprotection](/therapeutics/glp-1-agonists-neurodegeneration) — Drug class
- [Metabolic Syndrome and Alzheimer's Disease](/mechanisms/metabolic-dysfunction-neurodegeneration) — Mechanism
- [Diabetes and Dementia Risk](/diseases/diabetes-dementia-link) — Comorbidity
References
[Diabetes and Alzheimer's disease: shared genetic and cellular mechanisms. Alzheimer's & Dementia (2021)](https://doi.org/10.1002/alz.12343)
[GLP-1 receptor agonists for neuroprotection in Alzheimer's disease. Nature Reviews Neurology (2023)](https://doi.org/10.1038/s41582-023-00765-6)
[Metabolic dysfunction in Alzheimer's disease. Nature Reviews Disease Primers (2022)](https://doi.org/10.1038/s41582-022-00699-0)
[Integrated Alzheimer's Disease Rating Scale (iADRS). Journal of Prevention of Alzheimer's Disease (2017)](https://doi.org/10.14283/jpad.2017.32)
[Type 3 diabetes: a link between Alzheimer's disease and diabetes. CNS Drugs (2021)](https://doi.org/10.1007/s40263-021-00830-5)